First patients receive experimental lymphoma drug in groundbreaking immune therapy trial
NCT ID NCT05737628
Summary
This is the first study in people testing a new immune-boosting drug called BYON4228, both alone and combined with an existing lymphoma drug (rituximab). It aims to find safe doses and see if it helps patients whose B-cell non-Hodgkin's lymphoma has returned or hasn't responded to at least two prior treatments. The research will measure side effects and whether the treatment shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Spedali Civili di Brescia
Brescia, Italy
-
Centro Integral Oncológico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
IRCCS Ospedale San Raffaele
Milan, Italy
-
Institut Català d'Oncologia
Barcelona, Spain
-
Instituto Europeo di Oncologia
Milan, Italy
-
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST
Ravenna, Italy
-
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS
Candiolo, Italy
-
Radboud UMC
Nijmegen, Netherlands
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
University Hospitals Plymouth NHS Trust
Plymouth, United Kingdom
-
Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands
Conditions
Explore the condition pages connected to this study.